A Randomized Study of Ibrutinib Plus Obinutuzumab vs Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (A041702)
A Randomized Study of Ibrutinib Plus Obinutuzumab vs Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (A041702)
Trial Category:
Hematologic
Phase
III
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
